Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Intelligence Pricing Strategies Generic Drugs

Pantoprazole Leads Off UK Price Spikes In June

Pricewatch UK – June 2023

  • Data

Executive Summary

Amid triple-digit-percentage average price rises for several generic molecules in the UK during June 2023, pantoprazole topped the list.

You may also be interested in...



July Wholesaler Hike Sees UK Olanzapine Prices Spike

July brought UK price spikes for multiple presentations of generic olanzapine orodispersible tablets. Market researcher WaveData reveals the reason behind the increases.

UK Olanzapine Prices Rocket Up In May

Three presentations of olanzapine orodispersible tablets topped our table of the UK generics market’s Biggest Risers for May 2023.

Sandoz Prepares For European Natalizumab Launch As Approval Arrives

As it announced the formal European Commission approval of its partnered Polpharma Biologics-developed Tyruko natalizumab biosimilar to Tysabri, Sandoz offered Generics Bulletin a timeframe for its expected launch in Europe.

Table

View full table

Topics

Tags:
Market Intelligence Pricing Strategies Generic Drugs
Latest Headlines

Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’

Not In 2023 After All? FDA Turns Down Approval For Coherus’ On-Body Pegfilgrastim

Sandoz Prepares For European Natalizumab Launch As Approval Arrives

US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage

See All
UsernamePublicRestriction

Register

GB152839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By